Welcome to our dedicated page for Neurocrine Biosciences news (Ticker: NBIX), a resource for investors and traders seeking the latest updates and insights on Neurocrine Biosciences stock.
Neurocrine Biosciences Inc. reports biopharmaceutical developments across neurological, psychiatric, endocrine and immunological disorders. Recurring updates include commercial and clinical information for INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease, CRENESSITY for classic congenital adrenal hyperplasia, and approved therapies for endometriosis and uterine fibroids.
Company news also covers CAHtalyst clinical data, peer-reviewed publications on glucocorticoid dosing and the Tardive Dyskinesia Impact Scale, pipeline programs such as NBIP-'2118, financial results, healthcare conference participation, and governance or capital-structure matters tied to Neurocrine's public-company reporting.
Neurocrine Biosciences (Nasdaq: NBIX) reported real-world clinician survey data on mild tardive dyskinesia (TD) and INGREZZA capsules at the APA 2026 meeting. In a subgroup of 90 patients with mild TD, 90% had functional impairment. After starting INGREZZA, 96% showed improved uncontrolled movements, with 86% improving within four weeks. Clinicians also reported high rates of better functional status, independence, daily activities and work or school participation.
Neurocrine Biosciences (Nasdaq: NBIX) completed its acquisition of Soleno Therapeutics, expanding its rare disease portfolio with VYKAT XR, the first and only approved treatment for hyperphagia in Prader-Willi syndrome.
The all-cash deal values Soleno at $2.9 billion, with shareholders receiving $53.00 per share. A tender offer closed on May 15, 2026, with 46,356,114 shares (about 88.9%) tendered. A follow-on merger on May 18, 2026, made Soleno a wholly owned subsidiary of Neurocrine, and Soleno’s stock will cease trading on Nasdaq.
Neurocrine Biosciences (Nasdaq: NBIX) announced publication of the first peer-reviewed, expert-driven algorithms to guide glucocorticoid (GC) dose reduction after initiating CRENESSITY® (crinecerfont) for classic congenital adrenal hyperplasia (CAH) in pediatric (4–17 years) and adult patients.
The guidance targets pediatric GC dosing to the upper physiologic range (8–11 mg/m2/day hydrocortisone equivalents) and adult physiologic ranges (2–14 mg/m2/day), and emphasizes gradual, supervised reductions with biomarker and clinical monitoring.
Neurocrine Biosciences (Nasdaq: NBIX) reported first-quarter 2026 results with $811.0M total net product sales, up 44% YoY. INGREZZA sales were $656.9M (+20% YoY); CRENESSITY sales were $153.3M. GAAP net income was $197.9M ($1.91 diluted EPS). The company announced a definitive agreement to acquire Soleno Therapeutics for $2.9B, expected to close in Q2 2026, and reaffirmed 2026 INGREZZA sales guidance of $2.7–$2.8B.
Neurocrine Biosciences (Nasdaq: NBIX) will present at the Bank of America Health Care Conference 2026 on May 12, 2026 at 11:20 a.m. PT (2:20 p.m. ET) in Las Vegas. The presentation will be webcast live and available on the company's Investors site.
According to the company, a replay will be posted about one hour after the event and archived on the website for approximately one month. Neurocrine describes its business focus, FDA-approved products across neurology and endocrine indications, and a mid- to late-stage clinical pipeline.
Neurocrine Biosciences (NASDAQ: NBIX) released survey findings on May 4, 2026 showing substantial employment impacts from tardive dyskinesia (TD). About 1 in 5 surveyed working adults with TD quit their job due to symptoms and respondents missed an average of 8 hours of work or school per week prior to treatment.
The online Ipsos survey included 70 adults diagnosed with TD and 30 caregivers; employment analyses used a 59-person respondent base. The release highlights low treatment rates with VMAT2 inhibitors and high levels of undiagnosed TD.
Neurocrine Biosciences (Nasdaq: NBIX) initiated a Phase 1 first-in-human study of NBIP-'2118, a CRF2 peptide agonist for obesity, on May 4, 2026. The trial will test single ascending doses versus placebo in healthy-weight, overweight, and obese adults, with initial data expected in 2027.
NBIP-'2118 is designed for once-weekly subcutaneous dosing; preclinical data showed fat loss with preservation or increase of lean mass. Neurocrine is developing complementary programs including NBIP-'1968 (GLP-1/GIP/glucagon triple agonist) and CRF2-incretin conjugates.
Neurocrine Biosciences (Nasdaq: NBIX) presented two-year data from the Phase 3 CAHtalyst Pediatric study showing durable hormone control and reduced glucocorticoid exposure with CRENESSITY (crinecerfont) in children and adolescents with classic congenital adrenal hyperplasia (CAH).
Key results: sustained ACTH and 17‑OHP reductions to Month 24, mean GC dose fell from 16.4 to 13.2 mg/m²/day, BMI SDS and HOMA‑IR improved in relevant baseline subgroups, and >80% study retention with no new safety signals.
Neurocrine Biosciences (NASDAQ: NBIX) announced publication in The Journal of Clinical Psychiatry establishing a minimal clinically important difference (MCID) of four points on the Tardive Dyskinesia Impact Scale (TDIS).
The research shows TDIS captures patient‑reported physical, social and emotional improvements with INGREZZA (valbenazine) across KINECT 3, KINECT 4 and KINECT-PRO clinical studies, providing a clearer threshold to interpret meaningful treatment benefit.
Neurocrine Biosciences (Nasdaq: NBIX) presented two-year Phase 3 CAHtalyst Adult data showing sustained glucocorticoid (GC) dose reductions with CRENESSITY (crinecerfont) in adults with classic congenital adrenal hyperplasia.
At Month 24, 69% (103/149) reached physiologic GC dosing (≤11 mg/m2/day HCe); mean daily dose fell from 17.6 to 10.6 mg/m2/day HCe (−38%). Study retention exceeded 80% at two years with no new safety signals reported.